Diabetes Research and Clinical Practice
Pathology and pathogenetic mechanisms of diabetic neuropathy: Correlation with clinical signs and symptoms
Introduction
Functional and structural impairments of peripheral nervous system are generally defined as diabetic neuropathy and its diagnosis is based on the exclusion of other diseases that may involve nervous system [1]. In fact, diabetic neuropathy is the most common complication of diabetes reaching 45–50% prevalence compared to 25–30% of retinopathy and 20% of nephropathy [2]. Recent advances in clinical evaluation and pathological studies on diabetic neuropathy revealed systematic changes of peripheral nervous systems. Signs and clinical symptoms can mostly be attributed to functional and structural alterations detected in peripheral nerves and many studies on experimental diabetic animal models have explored the pathogenetic mechanisms of this disorder [3], [4], [5]. In this communication, pathological background of diabetic neuropathy and underlying mechanisms at the molecular levels are briefly summarized. Recent results of clinical trials targeted for the pathogenetic factors are also introduced.
Section snippets
Pathological background and its clinical relevance
Most pathological studies to date on diabetic neuropathy were conducted on autopsy materials or biopsied samples of sural nerve obtained from diabetic patients with established neuropathy. From these systematic studies, it is well established that peripheral nerve pathology in diabetic patients is characterized by progressive nerve fiber loss with pan-modal fiber size pattern [3], [6] (Fig. 1). In particular, the nerve fiber degeneration is length-dependent and conspicuous in distal portion. It
Neuropathy in IGT
There are several lines of evidence that showed the presence of neurological involvement at the stage of IGT. The symptoms are the type of small fiber neuropathy pathologically characterized by loss of intradermal nerve fibers [8], [9]. The suggestion of an early presence of neuropathy in IGT is also supported by the Japanese epidemiological survey of IGT patients that showed high prevalence of subjects with loss of Achilles tendon reflex, reduced vibration perception threshold, or even reduced
Pathogenesis of neuropathy
As alluded earlier, it is essential to prevent or halt the development of diabetic neuropathy based on the information about the pathogenesis. Long term hyperglycemia elicits enhanced polyol pathway, increased nonenzymatic glycation of structural proteins, increased oxidative stress as well as altered protein kinase C activity and polyADP-ribose polymerase (PARP) activation that are all interrelated for the cause and development of neuropathy [3], [4], [5] (Fig. 3). These in turn activate or
Role of polyol pathway
Polyol pathway is a simple metabolic pathway converting glucose to sorbitol by enzyme of aldose reductase (AR), then converting sorbitol to fructose by sorbitol dehydrogenase (SDH). Under normoglycemic condition, glucose is metabolized to oxidative glycolytic pathway with phosphorylated oxidation through mitochondria. They produce ATP energy by citric acid cycle. Under hyperglycemia, excessive glucose is converted to sorbitol by AR. During this process, NADPH is consumed as a coenzyme.
Results from studies on AR-transgenic animals
To explore detailed mechanisms how polyol pathway is involved in diabetic neuropathy and to develop specific inhibitors for human AR, transgenic mouse model overexpressing human AR is now available. Under galactose load, this model exhibits significant delay of motor nerve conduction velocity and nerve fiber atrophy with tissue accumulation of polyol (galactitol). In this setting, neither blood glucose levels nor insulin levels are altered. Hyperactivity of polyol pathway indeed causes
Results from clinical trials
For the treatment of diabetic neuropathy, two basic directions may be raised; one for the symptomatic treatment for signs and symptoms that the patients complain, another for the fundamental treatment based on the pathogenetic mechanisms. Symptomatic treatment may not be effective for the prevention or halting of the disease but should be good for pain or to alleviate other subjective symptoms, while fundamental treatment may not be effective to relieve the symptoms but able to halt or inhibit
Concluding remarks
Recent studies demonstrated that neuropathy is treatable and preventable disease and early diagnosis is essential for this condition. To this end, exploration of pathogenesis of diabetic complications is most important, and such efforts will eventually lead to better outcome in diabetic patients in long-run.
References (19)
- et al.
Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves
J. Neurol. Sci.
(2000) Diabetic neuropathies: a statement by the American Diabetes Association
Diabetes Care
(2005)- et al.
The epidemiology of diabetic neuropathy
Diabetes Rev.
(1999) Pathology and pathogenetic mechanisms of diabetic neuropathy
Diabetes Metab. Rev.
(1995)- et al.
Experimental diabetic neuropathy: an update
Diabetologia
(1999) Mitogen-activated protein kinases as glucose transducers for diabetic complications
Diabetologia
(1999)- et al.
Pathologic alterations in the diabetic neuropathies of humans: a review
J. Neuropathol. Exp. Neurol.
(1996) - et al.
Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group
Diabetes Care
(2000) - et al.
The spectrum of neuropathy in diabetes and impaired glucose tolerance
Neurology
(2003)
Cited by (132)
A neuroprotective effect of pentoxifylline in rats with diabetic neuropathy: Mitigation of inflammatory and vascular alterations
2024, International ImmunopharmacologyIntestinal parasites and diabetes: A systematic review and meta-analysis
2023, New Microbes and New InfectionsPathologic basis for diabetic neuropathy in humans
2022, Diabetic NeuropathyRole of innate immunity in chemotherapy-induced peripheral neuropathy
2021, Neuroscience LettersCitation Excerpt :Macrophage infiltration to DRG and sciatic nerve has also been shown after CCI in rats, intrapancreatic nerves in patients with neuropathic pain due to pancreatic cancer, and is found in the peripheral nerves of rats with experimental diabetic neuropathy (streptozotocin), but not in a murine model of Type 2 diabetic neuropathy (high fat diet) [35,79–81]. The relationship between macrophage infiltration, nociceptive behavior, and IENF loss may not hold for diabetic neuropathy since it also involves oxidative stress and cytokine release pathways that are triggered by hyperglycemia and features pathological changes to endothelial cells and capillaries in the endoneurium that do correlate with IENF loss in patients [82,83]. Rats treated with paclitaxel and vincristine also showed an increase in the number and activation of Langerhans cells (LC) as APC in the epidermis of the paw, and this was followed by loss of IENF [84].